Sarcopenia does not affect liver regeneration and postoperative course after a major hepatectomy. A prospective study on 125 patients using CT volumetry and HIDA scintigraphy.

liver regeneration major hepatectomy sarcopenia scintigraphy volumetry

Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
02 Apr 2024
Historique:
received: 15 11 2023
revised: 28 03 2024
accepted: 01 04 2024
medline: 5 4 2024
pubmed: 5 4 2024
entrez: 4 4 2024
Statut: aheadofprint

Résumé

Sarcopenia is a morbi-mortality risk factor in digestive surgery, though its impact after major hepatectomy (MH) remains unknown. This prospective pilot study investigated whether volume and function of a regenerating liver is influenced by body composition. From 2011 to 2016, 125 consecutive patients had computed tomography and 99mTc-labelled-mebrofenin SPECT-scintigraphy before and after MH at day 7 and 1 month for measurements of liver volumes and functions. L3 vertebra muscle mass identified sarcopenia. Primary endpoint was the impact of sarcopenia on regeneration capacities (i.e. volume/function changes and post-hepatectomy liver failure (PHLF) rate). Secondary endpoint was 3-month morbi-mortality. Sarcopenic patients (SP; N=69) were significantly older than non-sarcopenic (NSP), with lower BMI and more malignancies, but with comparable liver function/volume at baseline. Postoperatively, SP showed higher rates of ISGLS_PHLF (24.6% vs 10.9%; p=0.05) but with comparable rates of severe morbidity (23.2% vs 16.4%; p=0.35), overall (8.7% vs 3.6%; p=0.3) and PHLF-related mortality (8,7% vs 1.8%; p=0.075). After matching on the extent of resection or using propensity score, regeneration and PHLF rates were similar. This prospective study using first sequential SPECT-scintigraphy showed that sarcopenia by itself does not affect liver regeneration capacities and short-term postoperative course after MH.

Sections du résumé

BACKGROUND & OBJECTIVES OBJECTIVE
Sarcopenia is a morbi-mortality risk factor in digestive surgery, though its impact after major hepatectomy (MH) remains unknown. This prospective pilot study investigated whether volume and function of a regenerating liver is influenced by body composition.
METHODS METHODS
From 2011 to 2016, 125 consecutive patients had computed tomography and 99mTc-labelled-mebrofenin SPECT-scintigraphy before and after MH at day 7 and 1 month for measurements of liver volumes and functions. L3 vertebra muscle mass identified sarcopenia. Primary endpoint was the impact of sarcopenia on regeneration capacities (i.e. volume/function changes and post-hepatectomy liver failure (PHLF) rate). Secondary endpoint was 3-month morbi-mortality.
RESULTS RESULTS
Sarcopenic patients (SP; N=69) were significantly older than non-sarcopenic (NSP), with lower BMI and more malignancies, but with comparable liver function/volume at baseline. Postoperatively, SP showed higher rates of ISGLS_PHLF (24.6% vs 10.9%; p=0.05) but with comparable rates of severe morbidity (23.2% vs 16.4%; p=0.35), overall (8.7% vs 3.6%; p=0.3) and PHLF-related mortality (8,7% vs 1.8%; p=0.075). After matching on the extent of resection or using propensity score, regeneration and PHLF rates were similar.
CONCLUSION CONCLUSIONS
This prospective study using first sequential SPECT-scintigraphy showed that sarcopenia by itself does not affect liver regeneration capacities and short-term postoperative course after MH.

Identifiants

pubmed: 38574887
pii: S2210-7401(24)00053-6
doi: 10.1016/j.clinre.2024.102332
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102332

Informations de copyright

Copyright © 2024. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of competing interest No conflict of interest to disclose

Auteurs

Maxence Fulbert (M)

Department of Digestive Surgery and Transplantation, CHU Lille, Univ. Lille, F-59000 Lille, France.

Mehdi El Amrani (M)

Department of Digestive Surgery and Transplantation, CHU Lille, Univ. Lille, F-59000 Lille, France; CANTHER laboratory "Cancer Heterogeneity, Plasticity and Resistance to Therapies" UMR-S1277, Team "Mucins, Cancer and Drug Resistance", F-59000 Lille, France.

Clio Baillet (C)

Department of Nuclear Medicine, CHU Lille, Univ. Lille, F-59000 Lille, France.

Katia Lecolle (K)

Department of Digestive Surgery and Transplantation, CHU Lille, Univ. Lille, F-59000 Lille, France.

Olivier Ernst (O)

Department of Digestive Radiology, CHU Lille, Univ. Lille, F-59000 Lille, France.

Alexandre Louvet (A)

Department of Hepatogastroenterology, CHU Lille, Univ. Lille, F-59000 Lille, France.

François-René Pruvot (FR)

Department of Digestive Surgery and Transplantation, CHU Lille, Univ. Lille, F-59000 Lille, France.

Damien Huglo (D)

Department of Nuclear Medicine, CHU Lille, Univ. Lille, F-59000 Lille, France.

Stéphanie Truant (S)

Department of Digestive Surgery and Transplantation, CHU Lille, Univ. Lille, F-59000 Lille, France; CANTHER laboratory "Cancer Heterogeneity, Plasticity and Resistance to Therapies" UMR-S1277, Team "Mucins, Cancer and Drug Resistance", F-59000 Lille, France. Electronic address: stephanie.truant@chu-lille.fr.

Classifications MeSH